Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer [Yahoo! Finance]
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: Yahoo! Finance
best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Colin Hayward, MBBS, FFPM, as the company's Chief Medical Officer. Dr. Hayward brings more than 26 years of global experience in the healthcare industry, including leadership in oncology, haemato-oncology, and rare diseases, with the last six years focused on radiopharmaceuticals and translational medicine. Ratio Therapeutics (PRNewsfoto/Ratio Therapeutics Inc.) "Colin joins Ratio at an important time as we advance our radiopharmaceutical pipeline and further progress the ATLAS trial, a Phase 1/2 study of [Ac-225]-RTX-2358 in patients with relapsed or refractory soft tissue sarcomas," said Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio. "His extensive experience in clinical development and medical affairs will be invaluable in guiding the trial's design, execution, and oversight, ensuring we generate robust data while maintaining the highest standards of patie
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- 3 Reasons to Sell MYGN and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know [Yahoo! Finance]Yahoo! Finance
- 2 Unprofitable Stocks on Our Buy List and 1 We Brush Off [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics (MYGN) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
MYGN
Earnings
- 2/23/26 - Beat
MYGN
Sec Filings
- 3/9/26 - Form 4
- 3/5/26 - Form EFFECT
- 3/4/26 - Form 424B3
- MYGN's page on the SEC website